Mason, Gary E.

Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency

Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 857

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

Quality of Life Following Amputation or Limb Preservation in Patients with Lower Extremity Bone Sarcoma

Mason, G. E., Aung, L., Gall, S., Meyers, P. A., Butler, R., Krüg, S., Kim, M., Healey, J. H., & Gorlick, R. (2013) · Frontiers in Oncology

Sarcoma Diagnosis and TreatmentCancer survivorship and care

Cited by 81

Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report

Zhu, X., McDowell, M. M., Newman, W. C., Mason, G. E., Greene, S., & Tamber, M. S. (2017) · Journal of Neurosurgery: Pediatrics

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 53

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Chi, K. N. N., Castro, E., Attard, G., Smith, M. R., Sandhu, S. K., Efstathiou, E., Roubaud, G., Small, E. J. J., Gomes, A. J. P. D. S., Rathkopf, D., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 12